CROS NT

What CROS NT does

Alira Health is a global life sciences advisory and contract research organization (CRO) operating across the full product lifecycle for pharmaceutical, biotechnology, medical device, and digital health clients. The company is legally CMC Consulting Boston, Inc. (d/b/a Alira Health), headquartered in Framingham, Massachusetts, and grew from a boutique consultancy of fewer than 30 employees (acquired via leveraged buyout in 2015 by current CEO Gabriele Brambilla) to over 800 employees across the Americas, EMEA, and Asia-Pacific (13+ countries including the USA, UK, France, Germany, Italy, Spain, Switzerland, Ireland, Sweden, Denmark, the Netherlands, Portugal, Japan, and Australia). The firm is privately held and majority-controlled by its CEO, who also chairs the Drug Delivery Systems Center of Excellence; the Board was expanded in January 2026 with Bill Achtmeyer and George G. Montgomery (Chairman). The CROS NT biometrics operation, founded in Verona, Italy in 1992 (with bolt-on acquisitions of Stat-Tech Services in 2013 and MDSL International in 2014), is part of Alira Health's biometrics service line providing biostatistics, data management, and statistical programming for clinical trials.

The company's service portfolio is organized into Research and Clinical Development Solutions (Regulatory, Clinical, Biometrics, CMC, Clinical Development Consulting), Consulting (Management Consulting, Market Access, Patient Engagement, Transaction Advisory), Real-World Solutions, and a dedicated Biotech offering. Its proprietary technology surface centers on SpherePX™, a platform launched January 2025 for real-world evidence collection and patient engagement, and Health Storylines™, a digital patient engagement tool. Complementary intellectual property includes the Patient Engagement Certification program (launched June 2025) and a publishing franchise of annual industry reports covering biologics CDMO (the market reached $23.2B in 2025), medtech CDMO ($96.5B in 2025, projected to $143.6B by 2030 at 8.3% CAGR), and global drug delivery systems.

Revenue is generated through customized professional services engagements priced on a quote basis under multi-year contracts, supplemented by sales of industry research reports and the Patient Engagement Certification program. Go-to-market is direct enterprise sales supported by an event-driven presence (BIO, CPHI, MedTech World, ASCO, EULAR), the annual Global Payer Forum (2,000+ live attendees from 87 countries in 2025), and thought-leadership content. The company secured up to $100 million in growth debt from Symbiotic Capital in December 2024 to fund expansion, and maintains named engagements with Gustave Roussy (cancer prevention), Lipogems (knee osteoarthritis FDA IDE study), Scottsdale Research Institute (psilocybin for PTSD), and Infuse Life Science (Japan medical devices).

Name

CROS NT

Legal name

CMC Consulting Boston, Inc. d/b/a Alira Health

Website

https://crosnt.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

Alira Health is a global life sciences consultancy and CRO delivering integrated regulatory, clinical, biometrics, market access, and real-world evidence services to pharmaceutical, biotech, medical device, and digital health clients across 13+ countries.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Other Scientific and Technical Consulting Services (541690), Scientific Research and Development Services (5417)

akta.pro primary industry

Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)

akta.pro secondary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Biometrics services
• Clinical data management
• Biostatistics consulting
• Statistical programming
• Clinical research services

Headquarters

HQ city

Verona

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Strategic Consulting Services: Management consulting, market access consulting, regulatory consulting, transaction advisory, and clinical development consulting services provided to life sciences companies.
2. CRO Services: Clinical research organization services including clinical operations, biometrics, CMC (Chemistry, Manufacturing and Controls), and clinical development consulting for pharmaceutical and biotech clients.
3. Research and Reports: Market research reports and white papers on CDMO markets, biologics, medtech, drug delivery systems, and other healthcare sectors sold to clients and made available for download.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Core offering

CROS NT is a global team of passionate specialists that deliver innovative, high quality, tailored biometrics solutions. The company focuses on biometrics services for clinical research, including biostatistics, clinical data management, and statistical programming delivered to study sponsors.

Product overview

Alira Health is a global healthcare consultancy offering an integrated platform of strategic consulting, CRO (Contract Research Organization) services, and technology solutions. The company's portfolio centers on patient-enabled innovation through its technology platforms (SpherePX™ for real-world evidence collection and Health Storylines™ for patient engagement), complemented by a Patient Engagement Certification program. Services span the full product lifecycle including Regulatory, Clinical, Biometrics, CMC, Clinical Development Consulting, Management Consulting, Market Access, Patient Engagement, Transaction Advisory, and Real-World Solutions. The company serves life sciences organizations across pharmaceuticals, biotech, medical devices, and digital health to accelerate development, improve access, and deliver measurable patient outcomes.

Differentiator

Problem solved

Functional benefit

Brands

• SpherePX: Next-generation technology platform designed to drive RWE collection and elevate patient engagement and retention.
• Health Storylines
• RedCrow
• Patient Engagement Certification
• Global Payer Forum

Products and services

• Biometrics Solutions Tailored biometrics services for clinical research sponsors, encompassing biostatistics, clinical data management, and statistical programming delivered to pharmaceutical, biotech, and medical device companies running clinical trials.

Quantifiable outcome

• 96% of Global Payer Forum respondents reported improved value-based healthcare knowledge
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration13 records

Feature3 records

Partnerships

Twelve partnerships are on record, tiered regional, core and minor.

• Infuse Life ScienceregionalStrategic or Co-development Partner · 18 June 2026Regional partnership combining iLS's Japan-rooted medical device and diagnostics expertise with Alira Health's comprehensive global life sciences strategy focused on pharmaceuticals and biotech to advance healthcare innovation.
• Patient Focused Medicines Development (PFMD)coreStrategic or Co-development Partner · 28 April 2026Coalition dedicated to enabling patient engagement by providing frameworks and collaborative networks needed to make patient-centered healthcare a worldwide reality. Alira Health joined to advance patient-centered evidence generation.
• Autoimmune Neurology Alliance (AiNA)coreStrategic or Co-development Partner · 15 April 2026Launched AXIS Registry - a new initiative to advance research and improve patient care in autoimmune neurological diseases including myasthenia gravis. Registry will collect patient-centered information for 10 years.
• Wound Care Collaborative Community (WCCC)coreStrategic or Co-development Partner · 24 September 2025First Platinum CRO Partner of the Wound Care Collaborative Community, expanding ongoing work to advance wound healing innovation through patient-centered approaches.
• Gustave RoussycoreStrategic or Co-development Partner · 27 February 2025Commercial partner overseeing digital development of Project Interception - a pioneering cancer prevention initiative led by one of the world's top cancer research institutes.
• RepublicminorGTM or Marketing Partner · 6 June 2024Strategic partnership between RedCrow (Alira Health company) and Republic to reshape healthcare crowdfunding landscape. Republic has an investor network of over 3 million users.
• AseBiominorStrategic or Co-development Partner · 24 April 2024Second edition of Mentoring Program in Market Access for SMEs - supporting and driving market access for innovation from small Spanish biotechnology companies.
• BiocatminorStrategic or Co-development Partner · 24 April 2024Startup Support Program 2024 - promoting second annual program focused on helping advanced and emerging therapies companies in the BioRegion of Catalonia reach the market.
• American Podiatric Medical Association (APMA)minorStrategic or Co-development Partner · 27 March 2024Corporate membership to help advance APMA's Podiatric Registry - the largest professional association representing podiatrists, physicians and surgeons treating foot and ankle.
• FORWARDcoreStrategic or Co-development Partner · 7 November 2023Partnership with national database for rheumatic diseases to create enhanced patient registry for autoimmune disease Lupus.
• Myasthenia Gravis Foundation of America (MGFA)coreStrategic or Co-development Partner · 31 January 2023Partnership to relaunch and enhance patient registry for people with myasthenia gravis, capitalizing on technological advances for clinical research.
• MassMEDICminorStrategic or Co-development PartnerCollaboration on annual U.S. MedTech Contract Manufacturing (CDMO) reports; Massachusetts Medical Device Industry Council.

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Cytel: Cytel is a leading pure-play biostatistics and biometrics CRO offering statistical programming, data management, and adaptive trial design services to biopharma sponsors globally — the closest direct specialist peer to CROS NT in the biometrics CRO niche.
• Clario: Clario (formed from the merger of ERT and Bioclinica) provides clinical trial endpoint technologies and biometrics services including eCOA, imaging, and respiratory diagnostics, with deep biostatistics/data management capabilities that overlap directly with CROS NT's offering.
• eClinical Solutions: eClinical Solutions (elluminate platform) provides clinical data management, biostatistics, and analytics services to life sciences sponsors — a direct competitor to CROS NT in biometrics-focused clinical trial services.
• Premier Research: Premier Research is a mid-sized CRO with strong biometrics, biostatistics, and clinical development capabilities serving biotech and specialty pharma — a comparable-sized direct competitor to CROS NT in the specialist CRO segment.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a global mid-market CRO providing biometrics, biostatistics, and full-service clinical development — directly comparable to CROS NT on biometrics depth and target customer (mid-tier biopharma).
• Theorem Clinical Research: Theorem Clinical Research is a mid-sized CRO providing biometrics, data management, and clinical research services to biopharma — a directly comparable scale peer to CROS NT.

Broad incumbents

• IQVIA: IQVIA is the largest global CRO with extensive biometrics and biostatistics capabilities offered alongside its full-service clinical, commercial, and real-world evidence portfolio — a broad incumbent whose biometrics unit competes head-to-head with specialist CROs like CROS NT.
• ICON plc: ICON plc is a top-3 global CRO with substantial biostatistics, data management, and statistical programming services offered as part of its integrated clinical development platform — competes with CROS NT in biometrics work as part of larger bundled deals.
• Charles River Laboratories: Charles River Laboratories operates a global CRO/biopharma services business including biostatistics and clinical data management, serving as a broad incumbent competitor that frequently bundles biometrics with its larger discovery and development offerings.

Emerging players

• Medidata (Dassault Systèmes): Medidata provides the Rave clinical trial platform and increasingly offers biometrics-adjacent data management and analytics services — an emerging player whose technology-driven model intersects with traditional biometrics CROs like CROS NT.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights4 records

Customer concentration

• Xx.com/CROS_NT
• LinkedInlinkedin.com/company/cros-nt
• Instagraminstagram.com/alirahealth

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CROS NT